These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The current clinical status of gold therapy in rheumatic diseases. Kaye RL J Rheumatol Suppl; 1982; 8():124-31. PubMed ID: 6982338 [No Abstract] [Full Text] [Related]
6. [Dosage and adverse effects of commonly used antirheumatic agents]. Mathies H Int Z Klin Pharmakol Ther Toxikol; 1971 Dec; 5(3):320-6. PubMed ID: 5317064 [No Abstract] [Full Text] [Related]
7. A method of comparing the toxicities of disease suppressive agents: possible application to a comparison between D-penicillamine and chloroquine. Redda A; Anastassiades T Clin Invest Med; 1984; 7(1):65-71. PubMed ID: 6426836 [TBL] [Abstract][Full Text] [Related]
8. A comparative study of auranofin, gold sodium thiomalate, and D-penicillamine in rheumatoid arthritis: a progress report. Barraclough D; Brook A; Brooks P; Boyden K; Thomas D; Tymms K J Rheumatol Suppl; 1982; 8():197-200. PubMed ID: 6813485 [TBL] [Abstract][Full Text] [Related]
9. Antirheumatic agents. Evens RP J Maine Med Assoc; 1979 Apr; 70(4):154-67. PubMed ID: 312309 [No Abstract] [Full Text] [Related]
10. [Problems of rheumatic therapy in pregnancy (author's transl)]. Bischof P MMW Munch Med Wochenschr; 1976 Oct; 118(41):1323-6. PubMed ID: 825725 [TBL] [Abstract][Full Text] [Related]
11. Absence of toxic or therapeutic interaction between penicillamine and previously administered gold in a trial of penicillamine in rheumatoid disease. Postgrad Med J; 1974 Aug; 50 Suppl 2():77-8. PubMed ID: 4619474 [No Abstract] [Full Text] [Related]
12. HLA antigens and toxicity to gold and penicillamine in rheumatoid arthritis. Scherak O; Smolen JS; Mayr WR; Mayrhofer F; Kolarz G; Thumb NJ J Rheumatol; 1984 Oct; 11(5):610-4. PubMed ID: 6439866 [TBL] [Abstract][Full Text] [Related]
13. [Gold therapy of rheumatic diseases]. Berndt H Z Arztl Fortbild (Jena); 1987; 81(9):416. PubMed ID: 3114970 [No Abstract] [Full Text] [Related]
14. "Disease-modifying" drugs in rheumatoid arthritis. Drug Ther Bull; 1985 Dec; 23(26):101-4. PubMed ID: 2866082 [No Abstract] [Full Text] [Related]
15. [Guidelines to the therapie of the most important rheumatic diseases (author's transl)]. Heimstädt P MMW Munch Med Wochenschr; 1977 Jun; 119(22):773-82. PubMed ID: 196190 [TBL] [Abstract][Full Text] [Related]
16. Penicillamine in the treatment of rheumatoid arthritis. Camp AV J Rheumatol Suppl; 1981; 7():103-6. PubMed ID: 6939871 [TBL] [Abstract][Full Text] [Related]
18. Penicillamine in rheumatic diseases: a prospective study of tolerance and efficacy. Munthe E; Kåss E J Rheumatol Suppl; 1981; 7():107-11. PubMed ID: 6785435 [TBL] [Abstract][Full Text] [Related]
19. [Problems of rheumatism therapy in pregnant women]. Bischof P; Kaiser H Verh Dtsch Ges Rheumatol; 1978; 5():276-7. PubMed ID: 309235 [No Abstract] [Full Text] [Related]
20. [Comparative evaluation of the effectiveness of gold preparations and D-penicillamine and their tolerance in rheumatoid arthritis. I. The effect on the indicators of their activity and tolerance]. Slobodina GA; Kanevskaia MZ; Krel' AA; Chichasova NV Revmatologiia (Mosk); 1989; (1):8-16. PubMed ID: 2501852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]